Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

Introduction: The multiorgan impact of moderate to severe coronavirus infections in the post-acute phase is still poorly understood. We aimed to evaluate the excess burden of multiorgan abnormalities after hospitalisation with COVID-19, evaluate their determinants, and explore associations with patient-related outcome measures. Methods: In a prospective, UK-wide, multicentre MRI follow-up study (C-MORE), adults (aged ≥18 years) discharged from hospital following COVID-19 who were included in Tier 2 of the Post-hospitalisation COVID-19 study (PHOSP-COVID) and contemporary controls with no evidence of previous COVID-19 (SARS-CoV-2 nucleocapsid antibody negative) underwent multiorgan MRI (lungs, heart, brain, liver, and kidneys) with quantitative and qualitative assessment of images and clinical adjudication when relevant. Individuals with end-stage renal failure or contraindications to MRI were excluded. Participants also underwent detailed recording of symptoms, and physiological and biochemical tests. The primary outcome was the excess burden of multiorgan abnormalities (two or more organs) relative to controls, with further adjustments for potential confounders. The C-MORE study is ongoing and is registered with ClinicalTrials.gov, NCT04510025. Findings: Of 2710 participants in Tier 2 of PHOSP-COVID, 531 were recruited across 13 UK-wide C-MORE sites. After exclusions, 259 C-MORE patients (mean age 57 years [SD 12]; 158 [61%] male and 101 [39%] female) who were discharged from hospital with PCR-confirmed or clinically diagnosed COVID-19 between March 1, 2020, and Nov 1, 2021, and 52 non-COVID-19 controls from the community (mean age 49 years [SD 14]; 30 [58%] male and 22 [42%] female) were included in the analysis. Patients were assessed at a median of 5·0 months (IQR 4·2–6·3) after hospital discharge. Compared with non-COVID-19 controls, patients were older, living with more obesity, and had more comorbidities. Multiorgan abnormalities on MRI were more frequent in patients than in controls (157 [61%] of 259 vs 14 [27%] of 52; p<0·0001) and independently associated with COVID-19 status (odds ratio [OR] 2·9 [95% CI 1·5–5·8]; padjusted=0·0023) after adjusting for relevant confounders. Compared with controls, patients were more likely to have MRI evidence of lung abnormalities (p=0·0001; parenchymal abnormalities), brain abnormalities (p<0·0001; more white matter hyperintensities and regional brain volume reduction), and kidney abnormalities (p=0·014; lower medullary T1 and loss of corticomedullary differentiation), whereas cardiac and liver MRI abnormalities were similar between patients and controls. Patients with multiorgan abnormalities were older (difference in mean age 7 years [95% CI 4–10]; mean age of 59·8 years [SD 11·7] with multiorgan abnormalities vs mean age of 52·8 years [11·9] without multiorgan abnormalities; p<0·0001), more likely to have three or more comorbidities (OR 2·47 [1·32–4·82]; padjusted=0·0059), and more likely to have a more severe acute infection (acute CRP >5mg/L, OR 3·55 [1·23–11·88]; padjusted=0·025) than those without multiorgan abnormalities. Presence of lung MRI abnormalities was associated with a two-fold higher risk of chest tightness, and multiorgan MRI abnormalities were associated with severe and very severe persistent physical and mental health impairment (PHOSP-COVID symptom clusters) after hospitalisation. Interpretation: After hospitalisation for COVID-19, people are at risk of multiorgan abnormalities in the medium term. Our findings emphasise the need for proactive multidisciplinary care pathways, with the potential for imaging to guide surveillance frequency and therapeutic stratification

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Cohort Profile: The TASO-CAN Cohort Collaboration

This study Cohort largely sample sizes that nationally representative databases permit facilitate identification of rare outcomes and emerging problems and the elucidation of more complex relationships involving the use of cARTSub-Saharan Africa has scaled-up access to combination anti-retroviral therapy (cART) at unprecedented rates, yet data on patient-related outcomes remain sparse. Representative databases that facilitate high quality collection, harmonization and analysis of HIV-related information from clinical and research related sites are needed. The large sample sizes that nationally representative databases permit facilitate identification of rare outcomes and emerging problems and the elucidation of more complex relationships involving the use of cART. These efforts also allow meaningful comparisons between regional treatment programmes that differ in their operational procedures and serve diverse communities in different settings. Unique features of individual sites exist, such as language used and cultural norms, research and care capacity, infrastructure development, personnel training and experience, and collection of data elements that differ in type, number, definition or method of laboratory. Furthermore, the use of innovative databases and informatics approaches can provide a principled approach to pool national data, and improve uniformity and consistency in data management in such heterogeneous settings

Intra-Plant Communication regarding Equipment Maintenance and Alerts (semester?), IPRO 303: Intra-Plant Communication IPRO 303 Midterm Report Sp07

IPRO 303 begins its first semester as a project designed to enhance the operations of both coal-burning power plants and the Smart Signal© Corporation. When critical equipment fails, it sends a shockwave throughout an organization and into its supply chain. Smart Signal’s EPI*Center software solution enables companies to fill the equipment performance gap between current operations and corporate objectives through early, actionable warning of any abnormal performance.Sponsorship: SmartSignalDeliverables for IPRO 303: Intra-Plant Communication regarding Equipment Maintenance and Alerts for the Spring 2007 semeste

Intra-Plant Communication regarding Equipment Maintenance and Alerts (semester?), IPRO 303

IPRO 303 begins its first semester as a project designed to enhance the operations of both coal-burning power plants and the Smart Signal© Corporation. When critical equipment fails, it sends a shockwave throughout an organization and into its supply chain. Smart Signal’s EPI*Center software solution enables companies to fill the equipment performance gap between current operations and corporate objectives through early, actionable warning of any abnormal performance.Sponsorship: SmartSignalDeliverables for IPRO 303: Intra-Plant Communication regarding Equipment Maintenance and Alerts for the Spring 2007 semeste

Intra-Plant Communication regarding Equipment Maintenance and Alerts (semester?), IPRO 303: Intra-Plant Communication IPRO 303 Poster Sp07

IPRO 303 begins its first semester as a project designed to enhance the operations of both coal-burning power plants and the Smart Signal© Corporation. When critical equipment fails, it sends a shockwave throughout an organization and into its supply chain. Smart Signal’s EPI*Center software solution enables companies to fill the equipment performance gap between current operations and corporate objectives through early, actionable warning of any abnormal performance.Sponsorship: SmartSignalDeliverables for IPRO 303: Intra-Plant Communication regarding Equipment Maintenance and Alerts for the Spring 2007 semeste

Intra-Plant Communication regarding Equipment Maintenance and Alerts (semester?), IPRO 303: Intra-Plant Communication IPRO 303 Project Plan Sp07

IPRO 303 begins its first semester as a project designed to enhance the operations of both coal-burning power plants and the Smart Signal© Corporation. When critical equipment fails, it sends a shockwave throughout an organization and into its supply chain. Smart Signal’s EPI*Center software solution enables companies to fill the equipment performance gap between current operations and corporate objectives through early, actionable warning of any abnormal performance.Sponsorship: SmartSignalDeliverables for IPRO 303: Intra-Plant Communication regarding Equipment Maintenance and Alerts for the Spring 2007 semeste

Intra-Plant Communication regarding Equipment Maintenance and Alerts (semester?), IPRO 303: Intra-Plant Communication IPRO 303 Abstract Sp07

IPRO 303 begins its first semester as a project designed to enhance the operations of both coal-burning power plants and the Smart Signal© Corporation. When critical equipment fails, it sends a shockwave throughout an organization and into its supply chain. Smart Signal’s EPI*Center software solution enables companies to fill the equipment performance gap between current operations and corporate objectives through early, actionable warning of any abnormal performance.Sponsorship: SmartSignalDeliverables for IPRO 303: Intra-Plant Communication regarding Equipment Maintenance and Alerts for the Spring 2007 semeste

Intra-Plant Communication regarding Equipment Maintenance and Alerts (semester?), IPRO 303: Intra-Plant Communication IPRO 303 IPRO Day Presentation Sp07

IPRO 303 begins its first semester as a project designed to enhance the operations of both coal-burning power plants and the Smart Signal© Corporation. When critical equipment fails, it sends a shockwave throughout an organization and into its supply chain. Smart Signal’s EPI*Center software solution enables companies to fill the equipment performance gap between current operations and corporate objectives through early, actionable warning of any abnormal performance.Sponsorship: SmartSignalDeliverables for IPRO 303: Intra-Plant Communication regarding Equipment Maintenance and Alerts for the Spring 2007 semeste